Prospects for the development of small molecular weight compounds to replace anti-tumour necrosis factor biological agents.
The advent of anti-TNF biological agents has been a massive advance in our treatment of RA and other inflammatory diseases. However, it is acknowledged that there are major drawbacks, the greatest being cost. There is, therefore, clearly a massive market for small molecular weight inhibitors that wo...
Πλήρης περιγραφή
Λεπτομέρειες βιβλιογραφικής εγγραφής
| Κύριοι συγγραφείς: |
Foxwell, B,
Andreakos, E,
Brennan, F,
Feldmann, M,
Smith, C,
Conron, M |
|---|
| Μορφή: | Journal article
|
|---|
| Γλώσσα: | English |
|---|
| Έκδοση: |
2003
|
|---|